Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of ILS 50.46 million. The enterprise value is 38.31 million.

Market Cap	50.46M
Enterprise Value	38.31M

Important Dates

The next estimated earnings date is Sunday, November 17, 2024.

Earnings Date	Nov 17, 2024
Ex-Dividend Date	n/a

Share Statistics

Evogene has 5.37 million shares outstanding. The number of shares has increased by 21.04% in one year.

Shares Outstanding	5.37M
Shares Change (YoY)	+21.04%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	1.57%
Owned by Institutions (%)	2.37%
Float	4.97M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.33
PB Ratio	4.15
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.51
EV / Sales	1.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.50

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.04.

Current Ratio	1.58
Quick Ratio	1.32
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.04
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -82.37% and return on invested capital (ROIC) is -50.33%.

Return on Equity (ROE)	-82.37%
Return on Assets (ROA)	-28.46%
Return on Capital (ROIC)	-50.33%
Revenue Per Employee	250,538
Profits Per Employee	-526,769
Employee Count	142
Asset Turnover	0.20
Inventory Turnover	3.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -54.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-54.84%
50-Day Moving Average	1,239.55
200-Day Moving Average	2,370.13
Relative Strength Index (RSI)	32.58
Average Volume (20 Days)	10,699

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evogene had revenue of ILS 35.58 million and -74.80 million in losses. Loss per share was -14.89.

Revenue	35.58M
Gross Profit	28.96M
Operating Income	-80.86M
Pretax Income	-79.19M
Net Income	-74.80M
EBITDA	-74.07M
EBIT	-80.86M
Loss Per Share	-14.89

Full Income Statement

Balance Sheet

The company has 78.72 million in cash and 3.05 million in debt, giving a net cash position of 75.67 million or 14.10 per share.

Cash & Cash Equivalents	78.72M
Total Debt	3.05M
Net Cash	75.67M
Net Cash Per Share	14.10
Equity (Book Value)	75.08M
Book Value Per Share	2.27
Working Capital	35.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -74.58 million and capital expenditures -1.78 million, giving a free cash flow of -76.36 million.

Operating Cash Flow	-74.58M
Capital Expenditures	-1.78M
Free Cash Flow	-76.36M
FCF Per Share	-14.23

Full Cash Flow Statement

Margins

Gross margin is 81.42%, with operating and profit margins of -227.27% and -210.26%.

Gross Margin	81.42%
Operating Margin	-227.27%
Pretax Margin	-222.59%
Profit Margin	-210.26%
EBITDA Margin	-208.19%
EBIT Margin	-227.27%
FCF Margin	-214.64%

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.04%
Shareholder Yield	-21.04%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 28, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

Evogene has an Altman Z-Score of -9.26. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.26
Piotroski F-Score	n/a